CD8A and neoplasm: In combination with rhein and atezolizumab, spleen and tumor CD8+ T cell ratios were significantly increased, and the levels of TNF-α, interleukin-6, and various apoptosis factors in the serum under combined therapy were significantly higher than those in other treatment groups, and the growth of breast tumors was effectively inhibited.